Half-Life Extension for Small-Format Biologics
Enhance the therapeutic options of VHH-based and other small biologic drugs by modulating renal clearance and enabling longer systemic exposure.
Why half-life extension can be important for small biologics
Many biologics below ~70 kDa—including VHH-based therapeutics—are rapidly cleared from circulation via renal filtration. This can result in short systemic exposure, frequent dosing, or continuous infusion, even when target engagement is strong.
Half-life extension is therefore a design consideration, not a rescue strategy. The choice of extension approach influences dosing, format architecture, translational models, and downstream manufacturability.
Diagram 1 – Renal filtration schematic
How It Works
Half-life extension approaches generally fall into two broad categories.
1. Increasing effective molecular size (renal filtration avoidance)
PEGylation
Covalent attachment of polyethylene glycol (PEG) increases apparent molecular size, reducing kidney filtration and proteolytic degradation. However, PEGylation can introduce safety, immunogenicity, and potency concerns due to altered physicochemical properties.
Repeating amino acid chains
Polypeptide-based approaches (e.g. XTEN, ELPylation) similarly increase molecular size and circulation time. These strategies may introduce developability trade-offs, including effects on stability, solubility, and activity.
Diagram 2 – Size-based half-life extension
2. Exploiting endogenous recycling pathways (FcRn-mediated recycling)
Certain plasma proteins—notably IgG and human serum albumin (HSA)—are protected from degradation through FcRn-mediated recycling.
IgG Fc fusion
Fusion to IgG Fc domains can extend half-life via FcRn recycling but may introduce immune effector functions, species-specific limitations, and format constraints.
HSA-based approaches
HSA is abundant, stable, and long-lived in circulation. Therapeutics associated with HSA can exploit FcRn recycling without necessarily introducing immune effector activity.
Diagram 3 – FcRn recycling pathway
3. Isogenica’s approach: ISOXTEND® (albumin-binding VHH)
ISOXTEND® is a humanised albumin-binding VHH designed to associate therapeutics with circulating albumin. By binding albumin with nanomolar affinity across a broad pH range, ISOXTEND® enables the therapeutic payload to benefit from albumin’s FcRn-mediated recycling and reduced renal clearance.
Key attributes described on the current page:
- In vivo validated with multi-species cross-reactivity (mouse and non-human primates)
- Reported extension of VHH half-life up to ~26 hours in mice (approximately equivalent to 16–19 days in humans)
- Compatible with mono- and multi-specific constructs and other biologic formats
Key Advantages
- Designed for small-format biologics, including VHH-based therapeutics
- Modular incorporation into mono- or multi-specific architectures
- Albumin-binding strategy avoids Fc mediated effector functions
- Demonstrated cross-species activity supports more robust preclinical evaluation through multi-species testing.
Half-life extension may be beneficial where sustained exposure improves efficacy, dosing practicality, or patient burden.
Representative use cases
- VHH-based therapeutics with rapid renal clearance
- Multi-specific constructs requiring balanced exposure
- Small biologics where frequent or continuous dosing is undesirable
ISOXTEND® application note
Tackling the challenge of short half-life for biological therapeutics
Short half-life can limit the development potential of VHH antibody-based therapeutics. ISOXTEND® is a humanised albumin-binding VHH antibody designed to extend exposure while maintaining functional characteristics.
Download the application note to see how ISOXTEND® can support mono- and multi-specific VHH antibody formats.
Publications
Building Smarter Therapeutics with VHH Bolt-Ons
VHH antibodies provide modular, high-performance components that can enhance biologics across multiple modalities. From albumin-binding half-life extension to bi-/multi-specific engineering and intracellular TPD, VHH bolt-ons enable more flexible, efficient and targeted therapeutic design. This article examines the key applications, design considerations e case studies that illustrate how VHH domains support next-generation engineered biologics. Read more
Building the next generation of precision oncology medicines
Biologic therapies have reshaped oncology, but they come with real limitations. Traditional monoclonal antibodies are large, complex molecules that can struggle with tumor penetration, slow development timelines, and costly manufacturing. In a field where time is critical and healthcare budgets are under increasing pressure, these constraints can hold back promising innovations. Read the article.
Comparing Risk in Synthetic vs Immune-based Discovery: Why Synthetic VHH Antibodies are the Future of Antibody Discovery
This case study delves into the development of anti-LRP6 VHH inhibitors that overcome these challenges. Isogenica’s VHH technology offers hope for more effective therapies targeting Wnt-related cancers.
Discuss half-life strategy for your biologic programme
Talk to our scientists if you want to include IsoXtend into your molecules or if you would like to discuss whether albumin-binding VHHs are appropriate for your target, format, and development stage.